Clinical trials: Advanced Lung Non-Small Cell Carcinoma
Non Small Cell Lung Cancer
Safety of Everolimus and Pemetrexed in Lung Cancer Patients
This study will evaluate the safety of everolimus in combination with pemetrexed when used as treatment in patients with non small cell lung cancer.
- Trial name
- NCT00434174
- Testing
- Everolimus, Pemetrexed
- Where
- 5 sites in Australia, Belgium and 1 more
- Volunteers
- 48 people
- Sponsor
- Novartis Pharmaceuticals
Non-small Cell Lung Cancer
Icotinib in Advanced Non-small Cell Lung Cancer (NSCLC) With Hepatic Insufficiency
The purpose of this study is to determine whether Icotinib is efficient and safe in treating advanced non-small cell lung cancer (NSCLC) patients with hepatic insufficiency.
- Trial name
- NCT02062515
- Testing
- icotinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Non-Small Cell Lung Cancer, Lung Cancer
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
This is an open-label, multicenter, Phase 1a/1b clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BG-60366, a highly potent, selective EGFR-mutation…
- Conditions
- Non-Small Cell Lung Cancer, Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)
- Trial name
- NCT06685718
- Testing
- BG-60366
- Where
- 29 sites in United States, Australia and 5 more
- Volunteers
- 33 people
- Sponsor
- BeOne Medicines
Cancer
Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer
This is a clinical trial examining the vascular disrupting agent NPI-2358 combined with docetaxel in patients with advanced non-small cell lung cancer (NSCLC).
- Trial name
- NCT00630110
- Testing
- docetaxel, NPI-2358 + docetaxel
- Where
- 36 sites in United States, Argentina and 4 more
- Volunteers
- 172 people
- Sponsor
- Nereus Pharmaceuticals, Inc.
Non-small Cell Lung Cancer (NSCLC)
Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%
The purpose was to evaluate the efficacy and safety of the combination of capmatinib with pembrolizumab compared to pembrolizumab alone as first-line treatment for subjects with locally advanced or metastatic NSCLC who have PD-L1…
- Trial name
- NCT04139317
- Testing
- Capmatinib, Pembrolizumab
- Where
- 36 sites in Australia, Belgium and 14 more
- Volunteers
- 76 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer…
- Conditions
- Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
- Trial name
- NCT07222566
- Testing
- PF-08634404, Pembrolizumab, Chemotherapy Regimen 1
- Where
- 484 sites in United States, Argentina and 18 more
- Volunteers
- 1,410 people
- Sponsor
- Pfizer
Non-Small Cell Lung Cancer NSCLC
Observational Study of Durvalumab in Patients With Non-small-cell Lung Cancer in the United Kingdom
This is a retrospective observational research study to describe the characteristics and real-world clinical outcomes of patients with locally advanced, unresectable Stage III non-small cell lung cancer receiving durvalumab in…
- Trial name
- CODAK (NCT04667312)
- Testing
- Durvalumab
- Where
- 10 sites in United Kingdom
- Volunteers
- 115 people
- Sponsor
- AstraZeneca
Solid Tumor, Non-small Cell Lung Cancer
Phase 1 Study of BPI-442096 in Advanced Solid Tumor Patients
A first-in-human study to evaluate the safety, tolerability and maximum tolerated dose (MTD) and establish the recommended phase 2 dose (RP2D) of BPI-442096, a SHP2 inhibitor, in patients with advanced solid tumors.
- Conditions
- Solid Tumor, Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer
- Trial name
- NCT05369312
- Testing
- BPI-442096
- Where
- 5 sites in China
- Volunteers
- 230 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Non-Small Cell Lung Cancer
A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC
This study will evaluate the efficacy, safety, pharmacokinetics and immunogenicity of RC148 injection as a single agent or in combination for the treatment of locally advanced or metastatic non-small cell lung cancer
- Trial name
- NCT06883630
- Testing
- RC148 plus Carboplatin and Paclitaxel/pemetrexed, RC148
- Where
- 24 sites in China
- Volunteers
- 121 people
- Sponsor
- RemeGen Co., Ltd.
Non-small Cell Lung Cancer, Extensive Disease Small Cell Lung Cancer
The Biomarker Exploratory Study in Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2)
This study is implemented in association with the study "J-TAIL-2" ; prospective multicenter observational study of atezolizumab in patients with unresectable, locally advanced or metastatic non-small cell lung cancer, UMIN study…
- Trial name
- NCT04818983
- Where
- 95 sites in Japan
- Volunteers
- 470 people
- Sponsor
- Chugai Pharmaceutical
Non-Small Cell Lung Cancer
The Purpose of Study is to Evaluate the Safety, Pharmacokinetics and Anti-tumor Effects of CKD-702 in Patients With Advanced or Metastatic Non-small Cell Lung Cancer Who Failed to Standard Therapy
The purpose of study is to evaluate the safety, pharmacokinetics and anti-tumor effects of CKD-702 as a monotherapy and to determine the Recommended Phase 2 Dose(RP2D) in patients with advanced or metastatic non-small cell lung…
- Trial name
- CKD-702 (NCT04667975)
- Testing
- CKD-702
- Where
- South Korea
- Volunteers
- 74 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Metastatic Non-small Cell Lung Cancer
Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010 in Patients With EGFR T790M Positive NSCLC
AC0010 is a novel, potent, small molecule irreversible tyrosine kinase inhibitor (TKI) that selectively targets mutant forms of the epidermal growth factor receptor (EGFR) while sparing wild-type (WT) EGFR.
- Trial name
- NCT02330367
- Testing
- AC0010
- Where
- 17 sites in China
- Volunteers
- 368 people
- Sponsor
- Hangzhou ACEA Pharmaceutical Research Co., Ltd.
Melanoma, Thyroid Cancer
Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.
The study objective is to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of orally administered PLX8394 in patients with advanced solid tumors.
- Conditions
- Melanoma, Thyroid Cancer, Colorectal Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT02012231
- Testing
- PLX8394
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Fore Biotherapeutics
Squamous Cell Carcinoma of Head and Neck, Non-small Cell Lung Cancer
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
A Phase 1/2, open label, multi-center study to evaluate the safety, efficacy and tolerability of alomfilimab as single agent and in combination with anti-PD-L1 (atezolizumab) in adult patients with selected advanced malignancies…
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Esophageal Cancer
- Trial name
- NCT03829501
- Testing
- Alomfilimab, Atezolizumab
- Where
- 22 sites in United States, Hungary and 4 more
- Volunteers
- 222 people
- Sponsor
- Kymab Limited
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
The purpose of this study is to compare the effectiveness of YK-029A as first-line treatment with that of platinum-based chemotherapy in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose…
- Trial name
- NCT05767892
- Testing
- YK-209A tablet, Pemetrexed+carboplatin/Cisplatin
- Where
- 52 sites in China
- Volunteers
- 350 people
- Sponsor
- Suzhou Puhe Pharmaceutical Technology Co., LTD
Non-small Cell Lung Cancer
A Safety and Efficacy Study of BCD-021 With Paclitaxel and Carboplatin Compared to Avastin With Paclitaxel and Carboplatin in Non-Small Cell Lung Cancer
BCD-021-02 is a double-blind randomized clinical trial comparing efficacy of BCD-021 (INN: bevacizumab) and paclitaxel + carboplatin to Avastin and paclitaxel + carboplatin in inoperable or advanced non-squamous NSCLC patients…
- Trial name
- NCT01763645
- Testing
- Bevacizumab, Paclitaxel, Carboplatin
- Where
- 44 sites in Belarus, India and 2 more
- Volunteers
- 353 people
- Sponsor
- Biocad
Advanced Non-small Cell Lung Cancer
Paclitaxel Plus Carboplatin With or Without Endostar in Patients With Advanced Non-small Cell Lung Cancer
In this randomized, double-blind, placebo-controlled, multicentre trial, 126 patients between July 5, 2007 and July 30, 2008 were enrolled from 10 centers.
- Trial name
- NCT00708812
- Testing
- Endostar(Recombinant Human Endostatin Injection), paclitaxel-carboplatin
- Where
- China
- Volunteers
- 126 people
- Sponsor
- Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd
Non-Small Cell Lung Cancer
A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)
This open-label, multicenter study will assess the safety, tolerability, and pharmacokinetics of intravenous (IV) dosing of atezolizumab in combination with oral erlotinib or alectinib in participants with NSCLC.
- Trial name
- NCT02013219
- Testing
- Alectinib, Atezolizumab, Erlotinib
- Where
- 17 sites in United States, France and 4 more
- Volunteers
- 52 people
- Sponsor
- Hoffmann-La Roche
Non-small Cell Lung Cancer, Glioblastoma Multiforme
Evaluation of GLR2007 for Advanced Solid Tumors
Evaluation of GLR2007 for Advanced Solid Tumors
- Trial name
- NCT04444427
- Testing
- GLR2007
- Where
- 4 sites in United States
- Volunteers
- 19 people
- Sponsor
- Gan and Lee Pharmaceuticals, USA
Carcinoma, Non-Small-Cell Lung
A Phase 1-2 XIAP Antisense AEG35156 With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer
This is an open-label multicenter, phase 1-2 study. Following determination of the recommended AEG35156 dose in combination with carboplatin and paclitaxel in the initial Phase 1 part of this study, additional patients will be…
- Trial name
- NCT00558922
- Testing
- AEG35156
- Where
- 6 sites in United States
- Volunteers
- 54 people
- Sponsor
- Aegera Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.